- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03191266
Transcranial Magnetic Stimulation for the Treatment of Veterans With Alcohol Use Disorders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Due to COVID-19 restrictions, active recruiting was suspended 31MAR20. Recruitment resumed 1SEP21
The purpose of this study is to evaluate the efficacy of intermittent theta burst repetitive transcranial magnetic stimulation (rTMS) as a treatment for Veterans with an alcohol use disorder (AUD) to decrease the exceedingly high rate of relapse associated with this condition.
At least 60% of those with AUD will experience a major relapse period within 6 months of treatment, irrespective of the intervention (psychosocial and/or pharmacological) employed. Consequently, the high prevalence of AUD and relapse following treatment in Veterans is associated with substantial resource allocation and costs for the DVA Health Care System. Current pharmacological and psychosocial interventions demonstrate only a moderate level of efficacy, which is reflected in the high rate of relapse in AUD.
rTMS is a neurostimulation method that is at the forefront of innovative, non-invasive, and safe treatments for AUD, and the disorders that commonly co-occur with AUD. To reduce the high rate of relapse in Veterans with AUD, it is necessary for interventions to more effectively address the associated neurobiological dysfunction and salient co-occurring conditions. Accordingly, additional rigorously controlled studies are required to determine if intermittent theta burst rTMS is an effective treatment for Veterans with AUD.
Participants will be recruited from VA Palo Alto Health Care System (VAPAHCS) residential substance abuse treatment clinics A double-blind randomized clinical trial with two groups: Active rTMS Treatment Group (Active rTMS) - will receive five treatments (two treatments per day) per week for 2 weeks. Sham Control Treatment group (i.e., identical rTMS experimental procedure, but no active stimulation) will receive the same frequency and duration of rTMS sessions. The proposed rTMS protocol is consistent with the FDA approved treatment regimen employed for major depressive disorders at the VAPAHCS MIRECC. Magnetic resonance imaging (MR) will be completed pre and post rTMS treatment and used to localize the left DLPFC in each participant to optimize rTMS for this region. Active and Sham rTMS groups will complete predictive measures [i.e., MR measures of anterior frontal glutamate level, blood flow, and tissue volume, diffusion tensor imaging, functional connectivity, task-based fMRI] and other outcome measures (i.e., measures of craving, mood, anxiety, neurocognition) immediately pre- and post-completion of the 2 weeks of rTMS sessions. Genetic markers (i.e., brain derived neurotrophic factor plasma levels and polymorphisms) will also be collected. Neuroimaging and genetic measures are necessary to establish potential biomarkers for prediction of rTMS treatment response, which is requisite for therapeutic optimization. For the 6 months following completion of active or sham rTMS treatment, participants will be contacted monthly, via telephone or in person, to complete a brief standardized measure of alcohol and substance use, craving, and psychiatric symptomatology to assess for changes in these variables over the previous 30 days.
This project will deliver completely novel data on the efficacy of intermittent theta burst rTMS for Veterans with AUD during the first 6 months following treatment. Monitoring over the entire first 6 months following treatment is crucial, given relapse within the first 6 months of treatment is robustly related to poor psychosocial functioning over the ensuing 1-3 years. The ultimate goal of this proposal is provide treatment that more effectively promotes sustained abstinence in the Veteran with AUD, as extended abstinence is robustly associated with optimum biomedical, neuropsychological, psychiatric, and psychosocial recovery and functioning.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Timothy C Durazzo, PhD
- Phone Number: (650) 493-5000
- Email: timothy.durazzo@va.gov
Study Contact Backup
- Name: Keith N Humphreys, PhD MA
- Phone Number: 22814 (650) 493-5000
- Email: Keith.Humphreys@va.gov
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304-1207
- Recruiting
- VA Palo Alto Health Care System, Palo Alto, CA
-
Contact:
- Timothy C Durazzo, PhD
- Phone Number: 650-493-5000
- Email: timothy.durazzo@va.gov
-
Contact:
- Jerome A Yesavage, MD
- Phone Number: 65147 (650) 493-5000
- Email: Jerome.Yesavage@va.gov
-
Principal Investigator:
- Timothy C. Durazzo, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The study will be open to male and females, regardless of race and ethnic origin, who are in active treatment for an alcohol use disorder (AUD).
- Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria for AUD, and alcohol is self-identified as primary substance of misuse.
- Actively in treatment at VA Palo Alto HCS Addiction Treatment Service, and able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participation in study procedures.
Participants will be accepted if taking medications specifically for the treatment of MDD, cigarette smoking, or for other psychiatric conditions.
- as long as the medications are not documented to lower seizure threshold
- must be stable on any psychotropic medication for at least 1 month prior to enrollment
- it would be clinically contraindicated to require participants to discontinue such medications for research.
- Participants will be abstinent from alcohol and non-prescribed substances for at least 7 consecutive days prior to active or sham rTMS and no participant demonstrates active acute withdrawal symptoms.
Exclusion Criteria:
Psychiatric:
- History of Schizophrenia Spectrum Disorders
- Bipolar Disorders
A current substance use disorder that exceeds the severity of the AUD
- based on DSM-5 diagnostic criteria
Current use of an FDA approved medication for treatment of AUD, i.e.:
- disulfiram
- acamprosate
- naltrexone
Active current suicidal intent or plan
- patients with a previous clinical flag for risk for suicide will be required to have an established safety plan involving their primary psychiatrist and the treatment team before entering the clinical trial
- Any form of previous rTMS or electroconvulsive treatment
Biomedical:
- Including but not limited to uncontrolled thyroid disease
- Unstable congestive heart failure
- Angina
- Other severe cardiac illness as defined by treatment regimen changes in the prior 3 months
- Cerebrovascular accident
- Cancer if < 1 year since end of treatment
- Unstable diabetes
- COPD requiring oxygen supplementation
- Alzheimer's disease
- Parkinson's disease
- Any biomedical implants with ferromagnetic content
- Neurostimulation devices
- Cardiac pacemakers or any magnetic resonance contraindications
- Traumatic brain injury with self-reported or observed loss of consciousness > 30 minutes
- Any primary or traumatically induced seizure disorder
General:
- Lack of fluency in English
Wechsler Adult Reading Test below the 7th percentile, i.e.:
- moderate or greater impairment in estimated general intelligence
Females who are pregnant or actively attempting pregnancy
- conservative exclusion for magnetic resonance research
- Current use of any medication or substance that is documented to lower seizure threshold or has been identified as a contraindication for rTMS treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: active rTMS
Active rTMS will receive an intermittent rTMS stimulation protocol.
|
Active rTMS will receive an intermittent rTMS stimulation protocol.
|
Sham Comparator: sham rTMS
Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
|
Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of abstinence from alcohol and other substances
Time Frame: 6 months
|
For the 6 months following completion of active or sham rTMS treatment, participants will be contacted monthly, via telephone or in person, to complete a brief standardized measure of alcohol and substance use, as well as craving, and psychiatric symptoms to assess for changes in these variables over the previous 30 days.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glutamate concentration in the left dorsolateral prefrontal cortex (as measured with single voxel spectroscopy)
Time Frame: Baseline
|
Determine if glutamate level can serve as a biomarker to predict rTMS treatment response in Veterans with AUD.
|
Baseline
|
Volume in anterior frontal cortical regions (as measured with FreeSurfer)
Time Frame: Baseline
|
Determine if volume in anterior frontal cortical regions can serve as biomarkers to predict rTMS treatment response in Veterans with AUD.
|
Baseline
|
Functional connectivity (as measured with resting state fMRI)
Time Frame: Baseline
|
Determine if functional connectivity can serve as a biomarker to predict rTMS treatment response in Veterans with AUD.
|
Baseline
|
BDNF polymorphisms (as measured with TaqMan genotyping assays or similar assays)
Time Frame: Baseline
|
Determine if BDNF polymorphisms can serve as biomarkers to predict rTMS treatment response in Veterans with AUD.
|
Baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Timothy C. Durazzo, PhD, VA Palo Alto Health Care System, Palo Alto, CA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D2303-R
- 1I01RX002303-01A2 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...RecruitingAlcohol Drinking | Substance Use | Alcohol Use Disorder | Drinking, Alcohol | Alcohol Use Disorder (AUD)United States
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingAlcohol Use Disorder (AUD)Germany
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompletedAlcohol Use Disorder (AUD)Uganda
-
University Hospital, Basel, SwitzerlandSolidarMedRecruitingAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateLesotho
Clinical Trials on Active rTMS
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Seoul National University HospitalUnknownTinnitusKorea, Republic of
-
University of Maryland, BaltimoreRecruiting
-
Institut GuttmannInstituto de Salud Carlos IIICompleted
-
Gaziler Physical Medicine and Rehabilitation Education...Active, not recruitingChronic StrokeTurkey
-
Ankara City Hospital BilkentActive, not recruitingChronic Spinal Cord DisorderTurkey
-
Centre Hospitalier du RouvrayUniversity Hospital, Rouen; Centre Hospitalier Sainte Anne, ParisNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityNot yet recruitingBrain Injuries | Gut Microbiota | Respiratory Function Impaired
-
Massachusetts General HospitalNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingLogopenic Variant Primary Progressive Aphasia | Non-fluent Variant Primary Progressive Aphasia | Semantic Variant Primary Progressive AphasiaUnited States